China SXT Pharmaceuticals Inc is a holding company mainly engaged in the research, development, manufacture, marketing and sales of Chinese traditional medicine products (TCMP). The Company sells different types of TCMP products, including Advanced TCMP and Regular TCMP. Advanced TCMP comprises of Directly-Oral-TCMP and After-Soaking-Oral TCMP. Regular TCMP is mainly for hospitals and drug stores for the treatment of various diseases or serving as dietary supplements. The Company sells its products under the brand Suxuantang.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
11/09/26	$2.560	+32.64%	14,162,896
10/09/26	$1.930	-9.81%	99,027
09/09/26	$2.140	-4.46%	51,608
08/09/26	$2.240	+0.45%	36,915
04/09/26	$2.230	+1.36%	50,526

Delayed Quote Nasdaq

More quotes

Market Closed - Nasdaq 00:00:00 12/09/2026 +04			5-day change	1st Jan Change
2.560 ^USD	+32.64%		+14.80%	-99.99%

08-05	Top Premarket Decliners	MT
07-30	Top Premarket Gainers	MT

Market Cap	3.38M 2.91M 2.76M 2.5M 4.69M 323M 4.72M 32.78M 12.6M 164M 12.7M 12.43M 520M	P/E 2025 *	-	P/E 2026	-
Enterprise Value	-23.82M -20.52M -19.43M -17.61M -33.04M -2.28B -33.21M -231M -88.74M -1.16B -89.45M -87.48M -3.66B	EV / Sales 2025	9.8x	EV / Sales 2026	-22.6x
Free-Float	66.63%	Yield 2025 *	-	Yield 2026	-

Markets		Quality
Nasdaq	SXTC	Delayed
CBOE	SXTC	Real-time
Tradegate	2RY2	Real-time
Deutsche Boerse AG	2RY2	Delayed

08-05	Top Premarket Decliners	MT
07-30	Top Premarket Gainers	MT
07-28	Top Premarket Decliners	MT
07-24	Top Premarket Decliners	MT
07-23	Top Premarket Decliners	MT
07-22	Top Premarket Gainers	MT
07-03	China SXT Pharmaceuticals, Inc. announced that it expects to receive $28.56 million in funding	CI
07-02	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2026	CI
01-08	Top Midday Gainers	MT
01-01	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2025	CI
31/07/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended March 31, 2025	CI
28/03/25	China SXT Pharmaceuticals, Inc. Reports Earnings Results for the Half Year Ended September 30, 2024	CI
17/03/25	China Sxt Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Requirement	MT

China SXT Pharmaceuticals, Inc. Stock

Stocks

SXTC

VGG2161P1734

Pharmaceuticals

Valuation : China SXT Pharmaceuticals, Inc.

Chart: China SXT Pharmaceuticals, Inc.

Latest news : China SXT Pharmaceuticals, Inc.

Analysts' recommendations : China SXT Pharmaceuticals, Inc.

Press Releases : China SXT Pharmaceuticals, Inc.

Quotes and Performance

Price Extremes

Managers and Directors : China SXT Pharmaceuticals, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

08-05	China SXT Pharmaceuticals, Inc. Announces Share Consolidation	AQ
07-25	Univest Securities, LLC Announces Closing of $9 Million Registered Direct Offering for its Client China SXT Pharmaceuticals Inc. (NASDAQ: SXTC)	AQ
07-23	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering	AQ
07-02	China SXT Pharmaceuticals : Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)	PU
03-24	China SXT Pharmaceuticals, Inc. Announces Share Re-classification	AQ

1 day	+32.64%
1 week	+14.80%
1 month	-27.07%
3 months	-98.58%
6 months	-98.53%
Current year	-99.99%

1 week	1.78	3
1 month	1.78	5.55
Current year	1.78	83,758.33
1 year	1.78	83,758.33
3 years	1.78	613,438.04
5 years	1.78	67,307,692.31
10 years	1.78	4,490,384,615.38

Manager	Title	Age	Since
Sze Beng Lim CEO	Chief Executive Officer	-	20/01/2025
Feng Zhou CEO	Chief Executive Officer	34	04/07/2017
Xiaodong Pan DFI	Director of Finance/CFO	49	31/01/2022

Director	Title	Age	Since
Feng Zhou CHM	Chairman	34	04/07/2017
Jun Zheng BRD	Director/Board Member	49	31/12/2018
Xiaodong Ji BRD	Director/Board Member	57	22/05/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHINA SXT PHARMACEUTICALS, INC.	+32.64%	+14.80%	-99.99%	-100.00%	3.38M
ELI LILLY AND COMPANY	-0.65%	-2.93%	+47.52%	+87.34%	994B
JOHNSON & JOHNSON	-0.29%	-3.51%	+48.78%	+63.27%	640B
ABBVIE INC.	+0.83%	+0.26%	+16.76%	+72.52%	454B
ROCHE HOLDING AG	-0.38%	-3.59%	+28.24%	+35.57%	337B
NOVARTIS AG	-0.09%	-13.54%	+10.08%	+26.87%	261B
ASTRAZENECA PLC	-0.43%	-2.48%	-2.07%	+11.48%	246B
AMGEN INC.	-1.34%	-13.70%	+33.47%	+44.18%	204B
NOVO NORDISK A/S	-3.44%	-7.51%	-20.08%	-59.58%	190B
GILEAD SCIENCES, INC.	-0.75%	-4.82%	+21.94%	+86.55%	178B
Average	+2.61%	-3.70%	+8.47%	+26.82%	350.48B
Weighted average by Cap.	-0.51%	-4.42%	+29.87%	+55.71%

	2025	2026
Net sales	1.74M 1.5M 1.42M 1.29M 2.42M 166M 2.43M 16.87M 6.49M 84.62M 6.54M 6.39M 267M	1.14M 981K 928K 842K 1.58M 109M 1.59M 11.03M 4.24M 55.31M 4.27M 4.18M 175M
Net income	-3.3M -2.85M -2.7M -2.44M -4.58M -316M -4.61M -32.01M -12.31M -161M -12.41M -12.13M -507M	-6.21M -5.35M -5.06M -4.59M -8.61M -593M -8.65M -60.12M -23.12M -302M -23.3M -22.79M -953M
Net Debt	-17.25M -14.87M -14.08M -12.76M -23.93M -1.65B -24.06M -167M -64.28M -839M -64.8M -63.37M -2.65B	-27.2M -23.44M -22.19M -20.11M -37.73M -2.6B -37.92M -264M -101M -1.32B -102M -99.91M -4.18B